GSK3β-IN-3 

GSK3β-IN-3 is an ATP-competitive GSK-3β inhibitor (IC₅₀ = 0.90 μM) with good blood-brain barrier permeability (Pe = 10.7 x 10-6 cm/s). GSK3β-IN-3 can reduce the phosphorylation level of tau protein in the BR5706 strain and reduce the deposition of Aβ aggregates in the CL2006 strain, and has the potential to be a candidate for the research of Alzheimer's disease (AD)^[1].

GSK3β-IN-3 (compound 66) (0.01-100 μM) inhibits GSK-3β with IC₅₀ = 0.90 μM^[1].

GSK3β-IN-3 (0-50 μM) shows ATP-competitive inhibition of the GSK-3β enzyme^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

GSK3β-IN-3 (compound 66) (10 μM) reduces p-Tau (Ser396) levels in the BR5706 strain in C. elegans^[1].

GSK3β-IN-3 (10 μM) increases quantity of thrashes, reduces Aβ deposition in the CL2006 C. elegans strain^[1].

GSK3β-IN-3 shows good stability in human microsomes^[1].

GSK3β-IN-3 has the potential to cross the BBB in PAMPA-BBB test^[1].

GSK3β-IN-3 has high plasma protein binding, shows plasma protein binding 96.4%^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

310.80

C₁₄H₁₅ClN₂O₂S

301359-45-5

CCOC(C1=C(NC(NC1C2=CC=CC=C2Cl)=S)C)=O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Sukanya S, et al. Exploring 2-Thioxo-1,2,3,4-tetrahydropyrimidines as Dual Acting GSK-3β/Aβ Aggregation Inhibitors: Implications for Alzheimer's Disease Treatment. Drug Dev Res. 2025 Jun;86(4):e70112.  [Content Brief]